摘要
目的:探讨新辅助化疗对口腔鳞癌(OSCC)患者生存率和生存质量的影响。方法:132例T3、T4OSCC患者随机分为2组:Ⅰ组(单纯手术)75例:Ⅱ组(新辅助化疗﹢手术)57例,应用SPSS10.0软件统计分析两组5年生存率和用华盛顿大学生存质量问卷评价两组患者的生存质量。结果:①Ⅰ组和Ⅱ组的5年生存率分别为42.8﹪、55.8﹪,两组间有显著性差异(P﹤0.05);新辅助化疗有效者和无效者5年生存率分别为66.5﹪、45.9﹪,两组间有显著性差异(P﹤0.05);Ⅱ组中新辅助化疗无效者和Ⅰ组5年生存率分别为45.9﹪、42.8﹪,两组间无显著性差异(P﹥0.05)。②Ⅱ组生存质量总分显著高于Ⅰ组(P﹤0.05);Ⅱ组中新辅助化疗有效者显著高于无效者(P﹤0.05);Ⅱ组中新辅助化疗无效者与Ⅰ组无显著性差异(P﹥0.05)。结论:有效的新辅助化疗能显著提高OSCC患者的生存率和生存质量。
Objective： To investigate the effects of neoadjuvant chemotherapy （NACT） on survival rate and quality of life （QOL） of the patients with Oral squamous cell carcinoma （OSCC）.Method： 132 patients with T3 and T4OSCC were divided randomly into two groups： group Ⅰ （surgery） 75cases： group Ⅱ （NACT＋surgery） 57cases. 5-year survival rate of different groups were analyzed by SPSS10.0 statistic software, UW-QOL questionnaire was used to evaluate QOL of different groups.Result： ①5-year survival rate of group Ⅰ and group Ⅱ were 42.8 % and 55.8 % respectively （,P 〈 0.05） ; 5-year survival rate of the patients who was response to NACT and was non-response to NACT were 66.5 % and 45.9 % respectively （P 〈 0.05） ： 5-year survival rate of the patients who was non-response to NACT and group Ⅰ were 45.9 % and 42.8 % respectively （P 〉 0.05） .②QOL of group Ⅱ was significantly higher than that of group Ⅰ （P 〈 0.05） ; QOL of the patients who was response to NACT was significantly higher than that of the patients who was non-response to NACT （P〈0.05） ; QOL were no significant statistical difference between group I and the patients who was non-response to NACT （P〉0.05）.Conclusion：Effective neoadjuvant chemotherapy can improve survival rate and quality of life of the patients with Oral squamous cell carcinoma.
出处
《临床口腔医学杂志》
2007年第1期41-42,共2页
Journal of Clinical Stomatology
基金
重庆市科委应用基础研究项目(2003-43)
重庆市卫生局科研项目(2-073)
重庆医科大学科技基金(XB200207)
关键词
新辅助化疗
鳞状细胞癌
口腔
生存率
生存质量
neoadjuvant chemotherapy
squamous cell carcinoma
oral
survival rate
quality of life
